Understanding the
Unmet Need
Major Safety and
Tolerability Challenges Unnecessary Exposure to
Extended Endocrine Therapy Side Effects Lead
to Noncompliance
About Breast Cancer Index (BCI)
About BCI How is BCI Used? Predictive Studies Prognostic Studies Health Economics Study
Patient Scenarios Ordering Information Videos News & Press
bioTheranostics Privacy Statement Terms and Conditions Site Map

bioTheranostics, Inc.
9640 Towne Centre Drive | Suite 200
San Diego, CA 92121
bioTheranostics.com

US and International: +1 (858) 587-5870
Fax: +1 (858) 587-5874
Client Services: +1 (877) 886-6739
Billing Information: +1 (858) 682-9279

© 2015 bioTheranostics, Inc.
Breast Cancer Index and BCI are service marks of bioTheranostics, Inc.

< Back

Tour the Test Report

Prognostic Score

  • 0 - 10
  • Individualized risk of late recurrence*

*If ordered at time of diagnosis, test report also provides overall (years 0-10), early (0-5 year), and late (5-10 year) risk of recurrence

Prognostic Study PROGNOSTIC STUDIES

Predictive Score

  • Predictive of likelihood of benefit from extended endocrine therapy
  • HIGH or LOW (binary result)
Predictive Study PREDICTIVE STUDIES

BCI is now covered by Medicare

No co-pay or out-of-pocket expenses »

# # # # # # # # # # # # # # # # # # # # # # # # #

Breast Cancer Index (BCI)

Use predictive power to personalize her path

Who is really likely to benefit from extended
endocrine therapy in ER+ early-stage breast cancer?
Only BCI helps you decide: extended or end Endocrine therapy at year 51-3

Extended endocrine therapy poses major safety and tolerability challenges.

Learn More
BCI is the first and only commercially available, validated biomarker test that offers both:1-3

Predictive results for the likelihood of benefit from extended endocrine therapy

Prognostic results for risk of late distant recurrence (Years 5 – 10)

Learn More
The Prognostic and Predictive
Power of BCI. Watch Now.
Watch Video
Lorem ipsum dolor sit amet.
Play video More Videos
Order BCI BCI Patient Website

References

  1. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.
  2. Sgroi DC, et al. Lancet Oncol. 2013;14:1067 – 76.
  3. Sgroi DC, et al. J Natl Cancer Inst. 2013;105:1036-1042.

Breast Cancer Index Indications for Use and Limitations

BCI provides a quantitative assessment of the likelihood of distant recurrence in patients diagnosed with ER+ node-negative breast cancer, and prediction of likelihood of benefit from extended (>5 year) endocrine therapy in patients who are recurrence-free after an initial 5 years of adjuvant endocrine therapy. Treatment decisions require correlation with all other clinical findings. This test was developed and its performance characteristics determined by bioTheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. bioTheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high-complexity clinical laboratory testing.